Zobrazeno 1 - 8
of 8
pro vyhledávání: '"M A, Austenfeld"'
Autor:
M. A. Austenfeld, Winston K. Mebust, Girish V. Shah, John W. Weigel, Mark J. Noble, Walter Rayford
Publikováno v:
The Prostate. 30:160-166
BACKGROUND Recent evidence suggests that muscarinic receptors induce mitogenesis in cells capable of undergoing cell proliferation. Human prostate gland is innervated by the autonomic nervous system and muscarinic receptors have been localized in the
Publikováno v:
The Prostate. 22:23-30
The expression of the mutant p53 tumor suppressor gene was evaluated in 33 human prostate carcinomas. Using an immunohistochemical method with monoclonal antibodies PAb 1801 and PAb 240, 26 (79%) tumors demonstrated positive immunostaining for mutant
Publikováno v:
The Prostate. 30(3)
Recent evidence suggests that muscarinic receptors induce mitogenesis in cells capable of undergoing cell proliferation. Human prostate gland is innervated by the autonomic nervous system and muscarinic receptors have been localized in the prostate g
Autor:
R G, Middleton, I M, Thompson, M S, Austenfeld, W H, Cooner, R J, Correa, R P, Gibbons, H C, Miller, J E, Oesterling, M I, Resnick, S R, Smalley
Publikováno v:
The Journal of urology. 154(6)
The American Urological Association convened the Prostate Cancer Clinical Guidelines Panel to analyze the literature regarding available methods for treating locally confined prostate cancer, and to make practice policy recommendations based on the t
Autor:
M S, Austenfeld
Publikováno v:
Seminars in urologic oncology. 13(3)
Serum prostate-specific antigen testing and systematic ultrasound-guided biopsy has improved our ability to diagnose low-stage, nonpalpable prostate cancer. With improvement of diagnostic sensitivity, the risk of finding clinically insignificant or "
Publikováno v:
The Journal of urology. 152(5 Pt 2)
Medical interventions are identified to be in need of practice guidelines based on several criteria, including uncertainty of therapeutic benefit, economic impact, variation in practice patterns and lack of objective data for new developments. Treatm
Autor:
M S, Austenfeld
Publikováno v:
Seminars in urology. 11(2)
Stage A1 prostate cancer implies indolence. If only well-differentiated low-volume tumors are considered, the rate of cancer growth, clinical progression, and prostate cancer death is exceedingly low. All but a very few of these patients will need ob
Autor:
M S, Austenfeld, B E, Davis
Publikováno v:
The Urologic clinics of North America. 17(4)
Stage D1 disease will be encountered in 20 per cent of patients by those who treat prostate cancer. There is marked heterogeneity among cancers discovered at this stage, with 5-year disease-free survival rates ranging from 0 to 95 per cent. Generally